宫内暴露于抗惊厥药物的新生儿的异常凝血酶原-II（维生素K缺乏诱导蛋白-II）状态
PIVKA-II (protein induced by vitamin K absence-II) status in newborns exposed to anticonvulsant drugs in utero.
作者信息
Anai T, Hirota Y, Oga M, Yoshimatsu J, Miyakawa I
机构信息
Department of Obstetrics and Gynecology, Medical College of Oita.
出版信息
Nihon Sanka Fujinka Gakkai Zasshi. 1991 Mar;43(3):347-50.
Using PIVKA-II and Hepaplastin test, 5 neonates exposed to anticonvulsant drugs in utero were assessed 5 days after birth. None showed any sign of clinical bleeding, but all had PIVKA-II values over 1 microgram/ml. In controls, only 96 of 1,166 (8.2%) neonates had PIVKA-II values over 1 microgram/ml. The difference in the incidence rate was significant (p less than 0.005). Three of 5 epileptic mothers received valproatic acid and/or diazepam but no barbiturates and/or hydantoin.
使用异常凝血酶原-II（PIVKA-II）和肝促凝血酶原激酶试验，对5名在子宫内接触过抗惊厥药物的新生儿在出生后5天进行了评估。无一例出现临床出血迹象，但所有新生儿的PIVKA-II值均超过1微克/毫升。在对照组中，1166名新生儿中只有96名（8.2%）的PIVKA-II值超过1微克/毫升。发病率差异具有统计学意义（p<0.005）。5名癫痫母亲中有3名使用了丙戊酸和/或地西泮，但未使用巴比妥类药物和/或苯妥英。
Zotero 插件